TVTX Travere Therapeutics, Inc.

NEUTRAL Impact: 2/10 8-K
Horizon months Filed Jun 16, 2026 Processed 2d 12h ago SEC 0001438533-26-000048
8-K context-dependent: Items 5.02
Latest settled — T+1d ⚠ clustered
TVTX ▲ +1.87% at T+1d
NEUTRAL call ✓ call won +1.87% · α vs SPY +1.09% · entry $54.14 → $55.15
Next anchor: T+5d in 5d
Last close $54.14 (close Jun 17) · -0.00% from $54.14 entry
Entry anchored
Jun 16, 03:59 PM ET
via Databento tick
T+1d
+1.87%
call +1.87% · α +1.09%
$55.15
settled yesterday
T+5d
call — · α —
in 5d
T+20d
call — · α —
in 26d
T+60d
call — · α —
in 3mo

Price Chart

Loading chart...

Executive Summary

Travere Therapeutics disclosed the planned retirement of Chief Research Officer William Rote, effective February 17, 2027, with an orderly transition to Jula Inrig, who becomes EVP, Head of R&D and CMO effective July 1, 2026. This is a routine executive succession with long notice and a named internal successor, carrying no immediate financial or operational implications.

Actionable Insight

No material impact on operations or stock. Monitor for any unexpected changes in the transition timeline or additional executive departures before February 2027, but this filing is a non-event for traders.

Key Facts

  • Chief Research Officer William Rote, Ph.D., notified the company of his retirement effective February 17, 2027, the 10-year anniversary of his employment.
  • Dr. Rote will continue in his current role through the retirement date and assist in the transition.
  • Jula Inrig, M.D., current Chief Medical Officer, will assume Dr. Rote's responsibilities and be named Executive Vice President, Head of Research & Development and Chief Medical Officer effective July 1, 2026.
  • The company expects to enter into a consulting arrangement with Dr. Rote post-retirement.

Financial Impact

Not specified

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
90% bullish (21 analysts)

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001438533-26-000048
Document: 0001438533-26-000048-index-headers.html0001438533-26-000048
Document: 0001438533-26-000048-index.html0001438533-26-000048
Document: 0001438533-26-000048.txt0001438533-26-000048
15 reports for TVTX
Performance horizon
100% Hit rate 7 of 7 directional calls best @ T+60▲ +49.98%Feb 28, 2026
Filters
Rows
Reports for TVTX — sortable, filterable
Type Now
Jun 16, 2026
2d ago
Insider Cluster
NEUTRAL ★ 2/10
$54.14 $55.15▲ +1.87%▲ +1.09%$54.14 (−0.00%)
Jun 16, 2026
2d ago
8-K
NEUTRAL ★ 2/10
$54.14 $55.15▲ +1.87%▲ +1.09%$54.14 (−0.00%)
Jun 12, 2026
6d ago
144
NEUTRAL ★ 2/10
$52.04 $53.80▲ +3.38%▲ +1.62%$54.14 (+4.04%)
Jun 2, 2026
16d ago
8-K
BULLISH ★ 6/10
$42.96 $45.20▲ +5.21%▲ +5.94%$54.14 (+26.02%)
May 15, 2026
4w ago
144
NEUTRAL ★ 2/10
$42.59 $42.89▲ +0.70%▲ +0.77%$54.14 (+27.12%)
May 5, 2026
6w ago
144
NEUTRAL ★ 2/10
$44.76 $42.66▼ −4.69%▼ −4.36%$54.14 (+20.96%)
May 4, 2026
6w ago
144
NEUTRAL ★ 3/10
$44.80 $44.80· 0.00%▼ −1.38%$54.14 (+20.85%)
May 1, 2026
7w ago
Insider Cluster
BEARISH ★ 6/10
$44.12 $44.91▼ −1.79%▼ −2.13%$54.14 (−22.71%)
Apr 15, 2026
9w ago
144
NEUTRAL ★ 3/10
$40.95 $39.54▼ −3.44%▼ −3.70%$54.14 (+32.21%)
Apr 15, 2026
9w ago
Insider Cluster
BEARISH ★ 7/10
$40.95 $39.54▲ +3.44%▲ +3.70%$54.14 (−32.21%)
Showing 10 of 15

US Market Status

Market Closed — Juneteenth — Opens Mon (76h 12m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access